Advertisement


William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

2024 ASCO Annual Meeting

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This year I presented an update of the CAPTIVATE study, which is a multi-center study, an international study, actually, of a combined targeted therapy for patients with chronic lymphocytic leukemia who were previously untreated. The treatment was for three months of ibrutinib monotherapy, followed by 12 months or 12 cycles of combined therapy, ibrutinib plus venetoclax. There were two cohorts in this study. We focused, in this presentation, on the fixed-duration cohort. So all the patients received the 12 cycles of combined therapy and then stopped treatment for follow-up. And this was a five-and-a-half-year update of these data. We've presented these data previously with earlier data cuts, but the overall summary of and important points that were presented at ASCO this year was we focused on patients with high-risk features. Those were patients who had 17p deletion or mutated TP53 or a complex karyotype. And we reported the outcomes for that subgroup of patients compared to individuals who didn't have those high-risk features. We saw a lower five-year progression-free survival rate for patients with high-risk features. We also saw a lower five-year progression-free survival rate for patients with an unmutated immunoglobulin gene compared to those who have a mutated immunoglobulin gene. But overall, we did not identify, or we could not estimate, the median progression-free survival for the whole group or for the subgroups. So these patients are doing exceptionally well with a median that extends beyond a five-year follow-up, which illustrates to us that it is a reasonable option to recommend for patients, even with a high-risk feature, this fixed duration treatment with combined targeted therapy. Again, this is an all-oral regimen. It did not include a CD20 antibody, and we saw very high undetectable MRD rates, which correlated with long progression-free survival. This trial, again, has been previously presented. This was a follow-up and longer follow-up data available. It has been an important regimen. It is approved in the European Union. It's not approved in the U.S., but we do have it on the NCCN guidelines. So it is a treatment option for our patients. One of the questions has been what is the optimal patient population for this regimen? My opinion is that patients who do very well with this regimen are patients who have an unmutated immunoglobulin gene, their MRD rates, undetectable MRD rate, is higher than patients with a mutated immunoglobulin gene, and it's a very well-tolerated combination for our patients. And so I think of this regimen when I have a patient who is younger than 70 and has an unmutated immunoglobulin gene as an ideal first-line treatment option for that patient population.

Related Videos

Issues in Oncology

Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool

Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI, and what’s coming for the next generation of medical school students.

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Breast Cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Advertisement

Advertisement




Advertisement